Story · Medicine & Biotech

Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn

2 outlets · first reported by Financial Times Health on · latest · 14 hours of coverage

Drugmaker’s potential acquisition of Ollin Biosciences is latest in glut of deals in biotechnology sector (Financial Times Health)

Coverage, in order

  1. first Financial Times Health UK mainstream
    Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn

    Drugmaker’s potential acquisition of Ollin Biosciences is latest in glut of deals in biotechnology sector

  2. Pharmaphorum UK indie
    J&J cuts $3.3bn deal to buy eye drug developer Ollin

    J&J cuts $3.3bn deal to buy eye drug developer Ollin Phil.Taylor Mon, 16/11/2026 - 14:16

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.